Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Johnson & Johnson Makes Major Neuro Play With $14.6B Intra-Cellular Buyout

January 14, 2025
Johnson & Johnson, one of the world's largest pharmaceutical companies, has announced its acquisition of psychiatric drug developer Intra-Cellular. The deal, valued at $14.6 billion, marks a significant move for J&J into the field of neurology. The company aims to expand its portfolio of drugs and therapies for neurological disorders, including schizophrenia and bipolar disorder. Intra-Cellular's innovative drug pipeline shows promising results in extending patient survival in lung cancer, which further strengthens J&J's position in the oncology market. Stock market experts recommend considering JNJ stock as a long-term investment, with an optimistic forecast for its growth potential. For accurate stock predictions and guidance, professionals from Stocks Prognosis are highly recommended.
If you want to leave a comment, then you need Login or Register





Other data for JNJ

Related data

JNJJuly 14, 2025Johnson & Johnson Innovates with New Product Launches  ~1 min.

Johnson & Johnson, a leading pharmaceutical company, continues to make waves in the industry with its latest submission of sNDA for the schizophrenia drug CAPLYTA to the FDA....

JNJMay 25, 2025Revolutionary Innovation: JNJ Johnson & Johnson Leads the Medical Industry with Groundbreaking Technology  ~1 min.

Johnson & Johnson, the renowned medical technology company, continues to be at the forefront of innovation in the industry....

JNJMarch 21, 2025Johnson & Johnson Neurovascular leader heads for the exit  ~1 min.

Mark Dickinson, the leader of Johnson & Johnson Neurovascular, has announced his departure from the company....

JNJMarch 20, 2025Johnson & Johnson Faces Shareholder Activism Over Human Rights and Executive Pay Proposals  ~2 min.

Mark Dickinson, the leader of Johnson & Johnson Neurovascular, is leaving the company, according to sources....

JNJMarch 19, 2025FDA Clears Johnson & Johnson Robot for Enhanced Bronchoscopy  ~1 min.

Johnson & Johnson's MedTech division has received clearance from the FDA for its enhanced robotic-assisted bronchoscopy system....

JNJMarch 18, 2025Johnson & Johnson MedTech Introduces New EP Neurovascular Leader  ~1 min.

Johnson & Johnson MedTech, a subsidiary of Johnson & Johnson, has appointed a new leader for its electrophysiology and neurovascular group....

JNJMarch 14, 2025Johnson & Johnson's Decades-Long Quest for Effective IBD Treatments  ~1 min.

Johnson & Johnson has been investing in research and development for decades in order to find effective treatments for inflammatory bowel disease (IBD)....

JNJFebruary 28, 2025Johnson & Johnson's Strong Performance Since Last Earnings Report Raises Expectations  ~1 min.

Johnson & Johnson (JNJ) has shown an impressive 8.9% increase in its stock price since the release of its last earnings report....

JNJFebruary 26, 2025The surgical devices I design for JJ speed healing and save lives  ~1 min.

Johnson & Johnson (JNJ) has been at the forefront of medical technology, constantly innovating and developing breakthrough surgical devices that not only speed up the healing process but also save lives....

JNJFebruary 18, 2025Johnson & Johnson reportedly wants to sell Cerenovus for 1B  ~1 min.

According to recent reports, Johnson & Johnson is considering selling its Cerenovus stroke business for 1 billion dollars....

JNJJanuary 15, 2025JJ to buy psychiatric drug developer Intra-Cellular for 14.6B  ~2 min.

In a major move to bolster its presence in the mental health sector, pharmaceutical giant JNJ Johnson & Johnson has announced its acquisition of Intra-Cellular Therapies for a staggering $14.6 billion....

ABBVNovember 14, 2024AbbVie Faces Setback as Schizophrenia Drug Trials Fall Short  ~2 min.

Pharmaceutical giant AbbVie Inc. (ABBV) experienced a significant drop in stock prices today, following disappointing results from their latest schizophrenia drug trials....

ABBVNovember 12, 2024AbbVie Stock Faces Setback as Schizophrenia Drug Trials Disappoint  ~1 min.

Shares of AbbVie Inc. (ABBV) took a hit today after the results of the company's schizophrenia drug trials fell short of expectations....

JNJJuly 14, 2025Johnson & Johnson Innovates with New Product Launches  ~1 min.

Johnson & Johnson, a leading pharmaceutical company, continues to make waves in the industry with its latest submission of sNDA for the schizophrenia drug CAPLYTA to the FDA....

ABBVNovember 16, 2024The Motley Fool - AbbVie Stock: Keep Calm And Buy The Dip  ~1 min.

AbbVie Inc. (ABBV) experienced a decline in stock value today after disappointing results from its schizophrenia drug trials. However, some investors may see this as a buying opportunity....